Avidity Biosciences — Investor Day (March 2024)
35 slides from Avidity Biosciences's investor day presentation, Mar 4, 2024
Slide 1: Transforming Myotonic Dystrophy
Investor & Analyst Event Series – Volume 8 TRANSFORMING MYOTONIC DYSTROPHY Global Phase 3 HARBOR Trial & Long-term MARINA-OLE Data March 4, 2024 NASDAQ: RNA | aviditybio.com
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking state
Slide 3: Our Vision
3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1
Slide 4: Delivering in 2024: 3 Data Readouts in 3 Clinical Programs
4 AOC 1044 in DMD44 ~900 patients in U.S. Delivering in 2024: 3 Data Readouts in 3 Clinical Programs in 3 Rare Diseases AOC 1044 in DMD44 ~900 patients in U.S. 1020 in FSHD ~16,000-38, 00 patients in U.S. Anticipate Phase 1/2 FORTITUDE preliminary data in ~half of participants in Q2 2024 AOC 1001 in
Slide 5: Goals for the Day
5 Goals for the Day Share global Phase 3 HARBORTM trial design • Regulatory agreement on study design • On-track to initiate in Q2 2024 Present long-term data from MARINA-OLETM • Consistent and durable improvement in multiple measures, including vHOT, hand grip, muscle strength and activities of dai
Slide 6: Avidity Management Team
6 Avidity Management Team John W. Day, M.D., Ph.D., Professor of Neurology and Pediatrics, and Director, Division of Neuromuscular Medicine, Stanford University School of Medicine G U E S T S P E A K E R Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO W. Michael Flanagan, Ph.D.
Slide 7: Agenda/Outline
7 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Advancing to Phase 3: HARBORTM Trial Steve Hughes, M.D., CMO • MARINA-OLETM Long-term Efficacy and Safety Data John W. Day, MD, PhD, Professor of Neurology and Pediatrics and Director, Division of Neuromuscular Medicin
Slide 8: DM1: Significant Patient Burden and Unmet Need
8 0 APPROVED THERAPIES DM1: Significant Patient Burden and Unmet Need >40,000 PEOPLE WITH DM1 IN THE US • Underrecognized, progressive & often fatal neuromuscular disease that primarily affects skeletal, cardiac & smooth muscle • Increases in severity from generation to generation • Significant impa
Slide 9: Initiating Global Phase 3 Study
9 Initiating Global Phase 3 Study • Regulatory agreement on study design • HARBORTM study designed for efficiency and speed of execution • On track to initiate in Q2 2024 del-desiran 4 mg/kg Q8W Placebo Duration of Placebo Controlled Study: 54 weeks HARBOR Open Label Extension Trial 1:1 Randomizatio
Slide 10: Phase 3 Trial: Design & Objectives
10 Phase 3 Trial: Design & Objectives • 4 mg/kg every 8 weeks; first dose of 2 mg/kg • N=150; Ages 16+ • 1:1 randomization • Primary analysis at Week 30; Placebo-control out to week 54 • Participants eligible to roll-over into an open label extension • ~40 global sites Video Hand Opening Time (vHOT
Slide 11: Agenda/Outline
11 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Advancing to Phase 3: HARBORTM Trial Steve Hughes, M.D., CMO • MARINA-OLETM Long-term Efficacy and Safety Data John W. Day, MD, PhD, Professor of Neurology and Pediatrics and Director, Division of Neuromuscular Medici
Slide 12: John W. Day, M.D., Ph.D., Stanford University School of Medicine
John W. Day, M.D., Ph.D., Stanford University School of Medicine Professor of Neurology, Pediatrics (Genetics) and Pathology, and Director of the Division of Neuromuscular Medicine John W. Day is Professor of Neurology, Pediatrics (Genetics) and Pathology, and Director of the Division of Neuromuscul
Slide 13: Recognizing the spectrum of DM1
Recognizing the spectrum of DM1 13
Slide 14: Myotonic Dystrophy Affects Multiple Systems
Myotonic Dystrophy Affects Multiple Systems Eye & Eyelids Hearing Mouth & Speech Skin and Hair Throat, Voice, Swallow Breathing, coughing Heart function & rhythm Stomach, Bowel Liver and Bile Muscle: Stiff, Fatigue, Pain, Weakness, Atrophy, Dystrophy Sleep Abnormalities Blood Abnormalities Hormone A
Slide 15: How does a non-coding CTG expansion cause DM?
How does a non-coding CTG expansion cause DM? Taneja, et al.,JCB 1995 RNA MBNL Co-Local Mankodi, et. al., HMG 10:2165; 2001 Tapscott, Science 289: 1701; 2000 15
Slide 16: Del-desiran Designed to Address Underlying Cause by Liberating Free MBNL
Del-desiran Designed to Address Underlying Cause of Myotonic Dystrophy by Liberating Free MBNL Del-desiran (AOC 1001) treatment Reduced mutant DMPK MBNL sequestered by CUG repeats of mutant DMPK AOC 1001 MBNL [M BN L] in f (fo ld c ha ng e fro m b as el in e) 2.5 2.0 1.5 1.0 0.5 * PBO (n=8) 1 mg/kg
Slide 17: Long-term Safety & Efficacy Data from MARINA-OLE Trial
Long-term Safety & Efficacy Data from MARINA-OLE Trial in Patients with DM1 17
Slide 18: Del-desiran: Favorable Long-term Safety and Tolerability
18 Del-desiran: Favorable Long-term Safety and Tolerability As of January 2024, data from MARINA-OLE • All 37 participants enrolled remain on study • All related AEs were mild or moderate • Most common related AEs reported in 2 or more participants: • Nausea • Headache • No discontinuations • No stu
Slide 19: END-DM1 Natural History Study: Understanding DM1 Disease Progression
19 • Non-interventional NHS aimed to advance the understanding of disease progression in DM1 patients • Focuses on clinical outcome assessments to support development of therapies for DM1 • 700 patient, 2 year study, ~ 20 centers • Designed and run by the Myotonic Dystrophy Clinical Research Network
Slide 20: END-DM1 Data Informed Design of the MARINA & Phase 3 HARBOR Trials
20 END-DM1 Data Informed Design of the MARINA® & Phase 3 HARBOR Trials Same endpoints measured Clinical trial sites overlap with MARINA® & HARBOR Contemporary data set based upon standard of care Hundreds of patients with at least one-year of follow-up in END-DM1 natural history study Presenting one
Slide 21: END-DM1: Disease Progression in Key Measures
END-DM1: Disease Progression in Key Measures END-DM1 Natural History (1 year) 4 mg/kg Q12W (1 year) ImprovingDeclining DM1 endpoints: reliable and relevant to myotonic dystrophy PPN = Percent predicted normal CNTL= percentile Error bars = SEM (standard error of the mean) Thanks to END-DM1 physicians
Slide 22: Del-desiran: Reversal of Disease Progression vs. Natural History
Del-desiran: Reversal of Disease Progression in MARINA-OLE vs. Natural History Key endpoints to be used in pivotal HARBOR study ImprovingDeclining PPN = Percent predicted normal CNTL= percentile Error bars = SEM (standard error of the mean) Thanks to END-DM1 physicians for reviewing and approving us
Slide 23: Del-desiran: Long-term Improvement in Myotonia
Del-desiran: Long-term Improvement in Myotonia Measured by video hand opening time (vHOT) in MARINA® and MARINA-OLE MARINA® data statistically significant at all assessment time points* Video Hand Opening Time (vHOT) Independently adjudicated Q6W Dosing Q13W Dosing SEM=standard error of the mean *Ba
Slide 24: Del-desiran: Long-term Improvement in Myotonia
Del-desiran: Long-term Improvement in Myotonia Baseline vHOT MARINA-OLE (1 year of 4 mg/kg) ` Participant from del-desiran 4 mg/kg Timepoint at Day 183 in MARINA-OLE Measured by video hand opening time (vHOT) in MARINA® and MARINA-OLE 24
Slide 25: Del-desiran: Long-term Improvement in Muscle Strength
Del-desiran: Long-term Improvement in Muscle Strength HG=hand grip; PPN=percent predicted normal; SEM=standard error of the mean Quantitative Muscle Testing (QMT) Hand Grip Elbow Extension & Elbow Flexion Knee Extension & Knee Flexion Ankle Dorsiflexion Hand Grip Strength Q6W Dosing Q13W Dosing Meas
Slide 26: Del-desiran: Long-term Improvement in Activities of Daily Living
*Day 360 excludes one participant who experienced an injury impairing their ability to perform mobility measures. CNTL= percentile SEM = standard error of the mean Measured by DM1-Activ Patient Reported Outcomes in MARINA® and MARINA-OLE DM1-Activ Q6W Dosing Q13W Dosing * 26 Del-desiran: Long-term I
Slide 27: MARINA-OLE Data Summary
27 Del-desiran 4 mg/kg • Demonstrated favorable long-term safety and tolerability • Showed reversal of disease progression in MARINA® and MARINA-OLE compared to END-DM1 natural history data • Provided consistent and durable improvements in multiple clinical endpoints Global HARBOR trial initiation Q
Slide 28: Agenda/Outline
28 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Advancing to Phase 3: HARBORTM Trial Steve Hughes, M.D., CMO • MARINA-OLE Long-term Efficacy and Safety Data John W. Day, MD, PhD, Professor of Neurology and Pediatrics and Director, Division of Neuromuscular Medicine
Slide 29: Patient Experience: Impact of del-desiran on their life
29 Patient Experience: Impact of del-desiran on their life I started this drug in June and like, two weeks after I took the first infusion, I went to open up a pop bottle, which I never would've been able to do. It was a twist pop bottle…and it opened right up. My strength was better, my outlook was
Slide 30: Patient Experience: Impact of del-desiran on their life
30 Patient Experience: Impact of del-desiran on their life Before the study I couldn't stand on my toes and since I've been going back to working out, I can actually stand on my toes again. So hopefully building up some strength. The myotonia, if I would make a fist, I wouldn't be able to open my ha
Slide 31: Patient Experience: Impact of del-desiran on their life
31 Patient Experience: Impact of del-desiran on their life I've noticed a really big difference in the fact that I used to be a really active person before I got more symptomatic. After a few rounds of the infusion, I've actually been able to get back to the gym and start working out, working with a
Slide 32: Agenda/Outline
32 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Advancing to Phase 3: HARBORTM Trial Steve Hughes, M.D., CMO • MARINA-OLE Long-term Efficacy and Safety Data John W. Day, MD, PhD, Professor of Neurology and Pediatrics and Director, Division of Neuromuscular Medicine
Slide 33: Our Vision
33 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1
Slide 34: Q&A
Investor & Analyst Event Series – Volume 8 TRANSFORMING MYOTONIC DYSTROPHY Global Phase 3 HARBOR Trial & Long-term MARINA-OLE Data Q&A March 4, 2024 NASDAQ: RNA | aviditybio.com
Slide 35: Transforming Myotonic Dystrophy
Investor & Analyst Event Series – Volume 8 TRANSFORMING MYOTONIC DYSTROPHY Global Phase 3 HARBOR Trial & Long-term MARINA-OLE Data March 4, 2024 NASDAQ: RNA | aviditybio.com